Gilead Sciences (NASDAQ:GILD) has agreed to pay $202M to settle accusations from the Department of Justice that the company used speaking engagements for doctors in which they were rewarded with payments, meals, and travel expenses as kickbacks to persuade them to prescribe
Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.
